What's happening
This bill prohibits anticompetitive "pay-for-delay" agreements that prevent or delay access to affordable generic or biosimilar drugs.
Why it matters
Shifts the legal burden to drug companies. The bill presumes certain settlements between brand-name and generic/biosimilar drug makers are anticompetitive and illegal, unless the companies can clearly prove the agreement is pro-competitive or justified by fair compensation for other goods/services; this raises the risk and scrutiny for companies considering such deals.
Broadly defines illegal “pay-for-delay” practices. The legislation considers not just cash payments, but any “thing of value” (like exclusive licenses or promises not to launch competing products) as potentially anticompetitive if given in exchange for delaying or limiting competition, closing loopholes often exploited in settlement agreements.
Provides for strong state enforcement and penalties. New York’s Attorney General is empowered to bring civil actions against violators, with penalties up to three times the value of the deal (or $20 million, whichever is greater), plus damages and restitution, making the financial consequences for illegal agreements potentially severe.
Limits legal defenses and restricts industry arguments. The bill outlines specific arguments that cannot be used as defenses—such as claims that generic entry would have been blocked by other patents or FDA delays—making it harder for companies to justify or defend potentially anticompetitive deals in court.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Block Pay-for-Delay Drug Deals
Plain English, a few words. Used as the page title.
Sponsors
History
- Committed to rules
- Advanced to third reading
- 2nd report cal.
- 1st report cal.1331
- Print number 4370b
- Amend and recommit to health
- Print number 4370a
- Amend and recommit to health
- Referred to health
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Keep Drug Prices Down
In Assembly Committee · Health · Sponsor Richard Gottfried
Full text
6 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
4370--B
2021-2022 Regular Sessions
IN SENATE
February 3, 2021
Introduced by Sens. BIAGGI, BROOKS, BROUK, COMRIE, GAUGHRAN, HOYLMAN, LIU, MANNION, MAY, MYRIE, RAMOS -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- recommitted to the Committee on Health in accordance with Senate Rule 6, sec. 8 -committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee
AN ACT to amend the public health law, in relation to preserving access to affordable drugs
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Article 2-A of the public health law is amended by adding a new title IV to read as follows:
TITLE IV
PRESERVING ACCESS TO AFFORDABLE DRUGS Section 282. Definitions.
283. Preserving access to affordable drugs.
§ 282. Definitions. For the purposes of this title, the following terms shall have the following meanings:
1. "ANDA" shall mean abbreviated new drug application as described by 505(j) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 335(j).
2. "ANDA filer" shall mean a party that owns or controls an ANDA filed with the federal food and drug administration or has the exclusive rights under that ANDA to distribute the ANDA product.
3. "Agreement" shall mean anything that would constitute an agreement under state law.
4. "Agreement resolving or settling a patent infringement claim" includes any agreement that is entered into within thirty days of the resolution or the settlement of the claim, or any other agreement that is contingent upon, provides a contingent condition for, or is otherwise
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD04644-04-2
related to the resolution or settlement of the claim. This shall include, but is not limited to, the following:
(a) Any agreement required to be provided to the federal trade commission or the antitrust division of the United States Department of Justice under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L. No. 108-173;
(b) Any agreement between a biosimilar or interchangeable product applicant and a reference product sponsor under the Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, that resolves patent claims between the applicant and sponsor.
5. "Biosimilar biological product application filer" shall mean a party that owns or controls a biosimilar biological product application filed with the federal food and drug administration pursuant to section 351(k) of the Public Health Service Act, 42 U.S.C. 262(k), for licensure of a biological product as biosimilar to, or interchangeable with, a reference product, or that has the exclusive rights under the application to distribute the biosimilar biological product.
6. "NDA" shall mean a new drug application.
7. "Nonreference drug filer" shall mean either:
(a) An ANDA filer;
(b) A company that seeks an abbreviated approval pathway for its drug product under 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355(b)(2); or
(c) A biosimilar biological product application filer, or company seeking FDA approval for a biosimilar under 42 U.S.C. 262.
8. "Nonreference drug product" shall mean the product to be manufactured under an ANDA or an application filed under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355(b), that is the subject of the patent infringement claim, a biosimilar biological product that is the product to be manufactured under the biosimilar biological product application that is the subject of the patent infringement claim, or both.
9. "Patent infringement" shall mean infringement of any patent or of any filed patent application, extension, reissue, renewal, division, continuation, continuation in part, reexamination, patent term restoration, patents of addition, and extensions thereof.
10. "Patent infringement claim" shall mean any allegation made to a nonreference drug filer, whether or not included in a complaint filed with a court of law, that its nonreference drug product or application infringes any patent held by, or exclusively licensed to, the reference drug holder.
11. "Reference drug holder" shall mean either:
(a) A brand holder that is any of the following:
(i) The holder of an approved NDA for a drug product application filed under section 505(b) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355(b);
(ii) A person owning or controlling enforcement of the patent listed in the approved drug products with therapeutic equivalence evaluations in connection with the NDA; or
(iii) The predecessors, subsidiaries, divisions, groups, and affiliates controlled by, controlling, or under common control with, any of the entities described in subparagraph (i) or (ii) of this paragraph, with control to be presumed by direct or indirect share ownership of fifty percent or greater, as well as the licensees, licensors, successors, and assigns of each of those entities; or
(b) A biological product license holder, which shall mean any of the following:
(i) The holder of an approved biological product license application for a biological drug product under section 351(a) of the Public Health Service Act, 42 U.S.C. 262(a);
(ii) A person owning or controlling enforcement of any patents that claim the biological product that is the subject of the approved biological patent license application; or
(iii) The predecessors, subsidiaries, divisions, groups, and affiliates controlled by, controlling, or under common control with, any of the entities described in subparagraph (i) or (ii) of this paragraph, with control to be presumed by direct or indirect share ownership of fifty percent or greater, as well as the licensees, licensors, successors, and assigns of each of those entities.
12. "Reference drug product" shall mean the product to be manufactured by the reference drug holder and includes both branded drugs of the NDA holder and the biologic drug product of the biologic product license applicant.
13. "Statutory exclusivity" shall mean those prohibitions on the approval of drug applications under clauses (ii) through (iv) of section 505(c)(3)(E), section 527 or section 505A of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355(c)(3)(E), on the licensing of biological product applications under section 262(k)(7) of Title 42 of the United States Code or section 262(m)(2) or (3) of Title 42 of the United States Code.
§ 283. Preserving access to affordable drugs. 1. (a) Except as provided in paragraph (c) of this subdivision, an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects and shall be a violation of this section if both of the following apply:
(i) A nonreference drug filer receives anything of value from another company asserting patent infringement, including, but not limited to, an exclusive license or a promise that the brand company will not launch an authorized generic version of its brand drug; and
(ii) The nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.
(b) As used in subparagraph (i) of paragraph (a) of this subdivision, "anything of value" shall be interpreted broadly to include any type of consideration, value or benefit a reference drug holder or nonreference drug filer could possibly obtain from the agreement. "Anything of value" shall not include a settlement of patent infringement claims in which the consideration granted by the reference drug holder to the nonreference drug filer as part of the resolution or settlement consists of only one or more of the following:
(i) The right to market the competing product in the United States before the expiration of either:
(A) A patent that is the basis for the patent infringement claim; or
(B) A patent right or other statutory exclusivity that would prevent the marketing of the drug;
(ii) A covenant not to sue on a claim that the nonreference drug product infringes a United States patent;
(iii) Compensation for saved reasonable future litigation expenses of the reference drug holder but only if both of the following are true:
(A) The total compensation for saved litigation expenses is reflected in budgets that the reference drug holder documented and adopted at least six months before the settlement; and
(B) The compensation shall not exceed the lower of the following:
(1) Seven million five hundred thousand dollars; or
(2) Five percent of the revenue that the nonreference drug filer projected or forecasted it would receive in the first three years of sales of its version of the reference drug documented at least twelve months before the settlement. If no projections or forecasts are available, the compensation shall not exceed two hundred fifty thousand dollars;
(iv) An agreement by the reference drug holder not to interfere with the nonreference drug filer's ability to secure and maintain regulatory approval to market the nonreference drug product or an agreement to facilitate the nonreference drug filer's ability to secure and maintain regulatory approval to market the nonreference drug product; or
(v) An agreement resolving a patent infringement claim in which the reference drug holder forgives the potential damages accrued by a nonreference drug filer for an at-risk launch of the nonreference drug product that is the subject of that claim.
(c) Parties to an agreement are not in violation of paragraph (a) of this subdivision if they can demonstrate by clear and convincing evidence that either of the following are met:
(i) The value received by the nonreference drug filer described in subparagraph (i) of paragraph (a) of this subdivision is a fair and reasonable compensation solely for other goods or services that the nonreference drug filer has promised to provide; or
(ii) The agreement has directly generated procompetitive benefits and the procompetitive benefits of the agreement outweigh the anticompetitive effects of the agreement.
2. In determining whether the parties to the agreement have met their burden under paragraph (c) of subdivision one of this section, a court of competent jurisdiction shall not consider any of the following:
(a) That entry into the marketplace could not have occurred until the expiration of the relevant patent exclusivity or that the agreement's provision for entry of the nonreference drug product before the expiration of any patent exclusivity means that the agreement is procompetitive within the meaning of subparagraph (ii) of paragraph (c) of subdivision one of this section;
(b) That any patent is enforceable and infringed by the nonreference drug filer in the absence of a final adjudication binding on the filer of those issues;
(c) That the agreement caused no delay in entry of the nonreference drug filer's drug product because of the lack of Federal Food and Drug Administration (FDA) approval of that or of another nonreference drug product; or
(d) That the agreement caused no harm or delay due to the possibility that the nonreference drug filer's drug product might infringe some patent that has not been asserted against the nonreference drug filer or that is not subject to a final and binding adjudication on that filer as to the patent's scope, enforceability, and infringement.
3. In determining whether the parties to the agreement have met their burden under paragraph (c) of subdivision one of this section, a court of competent jurisdiction shall presume that the relevant product market is that market consisting of the reference drug of the company alleging patent infringement and the drug product of the nonreference drug filer accused of infringement and any other biological product that is licensed as biosimilar or is an AB-rated generic to the reference product.
4. (a) This section shall not modify, impair, limit, or supersede the applicability of the antitrust laws of the state pursuant to article twenty-two of the general business law, unfair competition laws of the state pursuant to article twenty-two-A of the general business law or the availability of damages or remedies provided therein. This section shall not modify, impair, limit, or supersede the right of any drug company applicant to assert claims or counterclaims against any person, under the antitrust laws or other laws relating to unfair competition of the federal antitrust law or state law.
(b) If any provision of this subdivision, an amendment made to this subdivision, or the application of any provision or amendment to any person or circumstance is held to be unconstitutional, the remainder of this subdivision, the amendments made to this subdivision, and the application of the provisions of this subdivision or amendments to any person or circumstance shall not be affected.
5. (a)(i) Each person that violates or assists in the violation of this section shall forfeit and pay to the state a civil penalty sufficient to deter violations of this section, as follows:
(A) If the person who violated this section received any value due to that violation, an amount up to three times the value received by the party that is reasonably attributable to the violation of this section, or twenty million dollars, whichever is greater; or
(B) If the violator has not received anything of value as described in this subparagraph, an amount up to three times the value given to other parties to the agreement reasonably attributable to the violation of this section, or twenty million dollars.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law, in relation to preserving access to affordable drugs
Purpose of bill
To preserve access to affordable prescription drugs by banning pay-to- delay agreements.
Summary of specific provisions
Section 1 amends Article 2-a of the public health law by adding a new title IV to preserve access to prescription drugs by banning pay-to-de- lay agreements.
Read the full memo (635 words)
Section 2 establishes that if any clause, sentence, paragraph, subdivi- sion, section or part is found to be invalid or unenforceable, the judg- ment will not invalidate the remainder of the bill.
Section 3 establishes the effective date.
Justification
Rising prescription drug prices have been devastating to New Yorkers who depend on prescription drugs to keep them healthy. The growing number of brand-name and specialty drugs with prices of $100,000 or more has led many to question whether the costs associated with these products are defensible or sustainable. The timely availability of generic and biosi- milar drugs, which increase competition and help lower prices, play an important role in addressing these concerns.
Brand-name drug manufacturers often file patent infringement lawsuits against the first generic drug manufacturers to seek FDA approval for competing generic drugs. Rather than face the costs and uncertainty associated with litigation, some brand-name and generic drug manufactur- ers choose to enter into what is known as a pay-for-delay agreement, where the brand-name drug manufacturers compensates the generic drug manufacturer for keeping its product off the market for a certain amount of time. These agreements can be particularly problematic when they involve the first-to-file generic manufacturer, because no other generic manufacturer can enter the market until the first-to-file manufacturer has marketed its product for 180 days.
These pay-for-delay agreements provide financial benefits to drug manufacturers at the expense of consumers; the brand-name manufacturer can continue to charge monopoly prices, and the generic company is compensated for its inaction. The Federal Trade Commission (FTC) esti- mates that pay-for delay agreements cost American consumers $3.5 billion per year.
The FTC has found that pay-for-delay agreements prohibit generic entry for an average of nearly 17 months longer than patent settlement agree- ments without such payments. In the meantime, consumers must continue paying brand-name drug prices, which can be as much as 85 percent higher than the prices of their generic drug counterparts. Any delay in gener- ic entry results in a longer period of purchases at the full brand price and, correspondingly, fewer purchases at less expensive generic prices. This negatively impacts both consumers and other payers, including taxpayer-funded health programs, such as Medicaid.
Generic drugs have proven to be one of the safest and most effective ways for consumers to lower their prescription drug costs, and the use of generic drugs has been steadily increasing. These drugs should not be delayed from entering the marketplace.
Patients in New York -- and around the country -- are facing unaccepta- ble costs and a lack of transparency about how medication is priced. For too long we have allowed pharmaceutical companies to operate under lax regulations at the expense of patients. This bill makes it the presump- tion that an agreement resolving or settling a patent infringement claim in connection to the sale of a pharmaceutical product has anti-competi- tive effects if 1) a non reference drug filer receives anything of value from another company asserting patent infringement and 2) the non refer- ence drug filer agrees to forego research, development, manufacturing, marketing, or sale of the drug for a period of time. The legislation sets forth civil penalties for individuals who violate or assist in violating this section to ensure compliance.
Prior legislative history
New bill.
Fiscal implications
None.
Effective date
This act shall take effect on the sixtieth day after it shall have become a law.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.